Id: acc0773
Group: 2sens
Protein: Smad2
Gene Symbol: SMAD2
Protein Id: Q15796
Protein Name: SMAD2_HUMAN
PTM: phosphorylation
Site: Ser465
Site Sequence: MGSPSVRCSSMS---------
Disease Category: Cancer
Disease: Prostate Cancer
Disease Subtype:
Disease Cellline: LNCaP C4-2B
Disease Info:
Drug: apigenin
Drug Info: "Apigenin is a naturally occurring flavonoid compound with demonstrated potential as an antifungal agent in the preparation of drugs against human fungal infections, and it is also being researched in drug delivery systems such as solid lipid nanoparticles (APG-SLNP) to enhance stability and bioavailability. "
Effect: modulate
Effect Info: "Apigenin inhibits prostate carcinogenesis by suppressing the phosphorylation of Smad2/3, Src, FAK, and Akt."
Note:
Score: 4.0
Pubmed(PMID): 23359392
Sentence Index:
Sentence:

Sequence & Structure:

MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTPNTIDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

SMAD2-Ser118
Cancer Intensity
BRCA
COAD -1.1
HGSC
ccRCC 0.246
GBM
HNSC
LUAD
LUSC 0.854
non_ccRCC
PDAC
UCEC
SMAD2-Thr172
Cancer Intensity
BRCA 0.002
COAD -0.816
HGSC 1.954
ccRCC -0.467
GBM
HNSC -0.115
LUAD -0.6
LUSC 0.334
non_ccRCC -1.011
PDAC -0.765
UCEC 1.485

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 465 U Head and neck squamous cell carcinoma Phosphorylation 21281788 ;  35022323
S 465 U Marfan syndrome Phosphorylation 15731757
S 465 U Gastric cancer Phosphorylation 23934187

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: